NEW YORK – Digital pathology firm Paige announced Tuesday that its artificial intelligence-based prostate cancer detection solution and pathology viewer has been CE marked.
The technology is now available to European pathology practices as a result, the New York City-based company said.
The Paige Prostate solution and Insight viewer are vendor-neutral and allow pathologists to view whole digitized slides from different sites and scanners. They use AI-based modules to provide improved diagnostics and detect cancerous areas, and the Paige Prostate has achieved clinical grade accuracy, the company said.
Earlier this year, the US Food and Drug Administration granted breakthrough device designation to the company's AI-based tools.